NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a
clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel
treatments for patients with solid tumor cancers, today announced that James F. Oliviero, President and Chief Executive Officer,
will participate in two investor conferences in March.
- Oppenheimer’s 28th Annual Healthcare Conference: Checkpoint will host one-on-one meetings on
Wednesday, March 21, 2018, at the Westin New York Grand Central in New York City
- The Wall Street Investor Forum 26th Annual Growth Conference: Checkpoint will present a company
overview on Thursday, March 22, 2018, at 11:50 a.m. EDT at The University Club of New York in New York City
A live webcast of The Wall Street Investor Forum presentation will be available on the Events page of the
Investors & Media section of Checkpoint’s website: www.checkpointtx.com. An archived replay of the webcast will be available for approximately 30
days following the presentation.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint’s lead product
candidate is a fully-human monoclonal antibody licensed from the Dana-Farber Cancer Institute that targets programmed death-ligand
1 (“PD-L1”). Checkpoint commenced a Phase 1 clinical study for its anti-PD-L1 antibody, CK-301, in October 2017, evaluating the
safety and tolerability of CK-301 in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, and plans to
develop CK-301 as a treatment for patients with non-small cell lung cancer (“NSCLC”) and other solid tumors. In addition,
Checkpoint is developing a small-molecule, targeted anti-cancer agent, CK-101, for the treatment of patients with epidermal growth
factor receptor (“EGFR”) mutation-positive NSCLC. In September 2016, Checkpoint commenced the Phase 1 portion of a Phase 1/2
clinical study for CK-101. Checkpoint’s pipeline also includes antibodies that target glucocorticoid-induced TNFR-related protein
(“GITR”) and carbonic anhydrase IX (“CAIX”), in addition to oral, small-molecule, targeted anti-cancer agents that inhibit
bromodomain and extra-terminal (“BET”) proteins and poly (ADP-ribose) polymerase (“PARP”). Checkpoint is a majority-controlled
subsidiary of Fortress Biotech, Inc., and is headquartered in New York City. For more information, visit www.checkpointtx.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) (NASDAQ:FBIO) is a biopharmaceutical company dedicated to acquiring, developing and
commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress
and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development
programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and
management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensing
arrangements, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional
funding to support their research and development programs. For more information, visit www.fortressbiotech.com.
Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and any other statements that are not historical facts.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to
differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development
activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and
clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early
stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required
by law.
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Jeremy Feffer
Managing Director, LifeSci Advisors, LLC
(212) 915-2568
jeremy@lifesciadvisors.com
Media Relations Contact:
Laura Bagby
6 Degrees
(312) 448-8098
lbagby@6degreespr.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/067475f8-416e-4d5f-a60f-26b19ea068dd?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzE5MDMxMw==)